Rafarma Pharmaceuticals, Inc.

Equities

RAFA

US75062C1009

Market Closed - OTC Markets Other stock markets 10:56:18 2024-04-26 am EDT			5-day change	1st Jan Change
0.1105 ^USD	+8.33%		+2.31%	-57.71%

2021	RafarmaPharmaceuticals, Inc. to Add Major Component to the Tashkent Pharma Park	CI
2021	Rafarma Pharmaceuticals, Inc. to Expand Proton Therapy Centers	CI

Rafarma Pharmaceuticals Announces the Complete Restructuring of Existing EUR 90,000,000 Loan with VNeshconombank

April 02, 2014 at 09:10 am EDT

Rafarma Pharmaceuticals Inc. announced the complete restructuring of its existing EUR 90,000,000.00 loan with VNeshconombank (VEBank). Terms and conditions of the restructured loan include a 3-year deferment, or holiday, on all principal and interest payments thus greatly enhancing the financial stability of the company.

Latest news about Rafarma Pharmaceuticals, Inc.

RafarmaPharmaceuticals, Inc. to Add Major Component to the Tashkent Pharma Park	21-12-17	CI
Rafarma Pharmaceuticals, Inc. to Expand Proton Therapy Centers	21-05-07	CI
Rafarma Pharmaceuticals, Inc. Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of Uzbekistan	21-01-29	CI
Vaccines Lab Sdn Bhd Enters Master Strategic Joint Venture Agreement with Rafarma Pharmaceuticals Inc	20-12-15	CI
Rafarma Pharmaceuticals, Inc. Signs a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia	20-12-01	CI
R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc..	20-10-18	CI
Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the Board	20-09-18	CI
Rafarma Establishes Thailand Corporate Entity for Merger and Expansion Projects	20-08-25	CI
R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc..	20-08-03	CI
Rafarma Pharmaceuticals, Inc. Announces Finalization of the Agreement with Destination Marketing Group Co. Ltd	20-06-22	CI
Rafarma Pharmaceuticals, Inc. Announces Commencement of Tests for Its New Product Hempysleep	20-06-15	CI
Rafarma Appoints Vladislav N. Laskav as Board Member	20-04-06	CI
Rafarma Pharmaceuticals, Inc. Agrees Terms to Open Its First Specialized Cannabis Spa in Europe	20-03-23	CI
Rafarma Pharmaceuticals Inc. Officially Begun Research Programs with Khon Kaen University in Thailand	20-02-24	CI
Rafarma Announces Cooperative Research Programs with the Faculty of Medicine, Khon Kaen University, Thailand	20-02-10	CI
Rafarma Pharmaceuticals, Inc. Closes Exclusive Joint Venture Agreement with MTP Material Co. Ltd	20-01-21	CI
Rafarma Pharmaceuticals, Inc. Appoints Anucha Phetpheng as New Executive Vice-President for Thai Operations	20-01-09	CI
Rafarma to Commence Production in Thailand	19-08-23	CI
Rafarma Pharmaceuticals, Inc. Appoints Vladimir Dolgolenko as CEO and President	19-07-12	CI
Rafarma’s Blockchain Tech Ready for Thailand’s Approved Uses of Cannabis	19-07-08	CI
Panaxia Pharmaceutical Industries and Rafa Sign A Collaboration Agreement with PlantEXT to Research and Manufacture the First Medical Cannabis Suppositories Intended for Patients Suffering from Inflammatory Bowel Disease	19-05-01	CI
Open Joint Stock Company Protek completed the acquisition of Joint Stock Company Rafarma from Rafarma Pharmaceuticals, Inc..	17-04-17	CI
Rafarma Pharmaceuticals Inc. Appoints Mr. Bruno Horn as New President and Director	14-07-30	CI
Rafarma Pharmaceuticals Announces the Complete Restructuring of Existing EUR 90,000,000 Loan with VNeshconombank	14-04-02	CI
Rafarma Pharmaceuticals, Inc. announced that it has received $1.2 million in funding.	13-12-11	CI

Chart Rafarma Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Sector

More about the company